# Marimed Inc.: financial statements, quarterly

MRMD · OTC · CIK 1522767 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mrmd.md) · [Financials](/companies/mrmd/financials.md) · [Filings](/companies/mrmd/filings.md) · [Insiders](/companies/mrmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mrmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [38.8](/filings/0001522767-24-000091.md) | [38.9 d](/filings/0001522767-25-000014.md) | [37.9](/filings/0001522767-25-000052.md) | [40.4](/filings/0001522767-25-000169.md) | [40.6](/filings/0001522767-25-000224.md) | [38.9 d](/filings/0001522767-26-000030.md) | [37.9](/filings/0001522767-26-000073.md) | [39.5](/filings/0001522767-26-000167.md) | [40.8](/filings/0001522767-25-000224.md) | [41.7 d](/filings/0001522767-26-000030.md) | [39.5](/filings/0001522767-26-000073.md) | [41.9](/filings/0001522767-26-000167.md) |
| Cost of revenue | $m | [22.0](/filings/0001522767-24-000091.md) | [21.6 d](/filings/0001522767-25-000014.md) | [21.5](/filings/0001522767-25-000052.md) | [23.5](/filings/0001522767-25-000169.md) | [23.8](/filings/0001522767-25-000224.md) | [26.3 d](/filings/0001522767-26-000030.md) | [22.8](/filings/0001522767-26-000073.md) | [23.6](/filings/0001522767-26-000167.md) | [24.4](/filings/0001522767-25-000224.md) | [31.1 d](/filings/0001522767-26-000030.md) | [24.2](/filings/0001522767-26-000073.md) | [25.7](/filings/0001522767-26-000167.md) |
| Gross profit | $m | [16.8](/filings/0001522767-24-000091.md) | [17.3 d](/filings/0001522767-25-000014.md) | [16.5](/filings/0001522767-25-000052.md) | [16.9](/filings/0001522767-25-000169.md) | [16.8](/filings/0001522767-25-000224.md) | [12.7 d](/filings/0001522767-26-000030.md) | [15.1](/filings/0001522767-26-000073.md) | [15.9](/filings/0001522767-26-000167.md) | [16.4](/filings/0001522767-25-000224.md) | [10.5 d](/filings/0001522767-26-000030.md) | [15.3](/filings/0001522767-26-000073.md) | [16.2](/filings/0001522767-26-000167.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [3.3](/filings/0001522767-24-000091.md) | [2.4 d](/filings/0001522767-25-000014.md) | [2.0](/filings/0001522767-25-000052.md) | [1.0](/filings/0001522767-25-000169.md) | [1.3](/filings/0001522767-25-000224.md) | [(1.5) d](/filings/0001522767-26-000030.md) | [(0.9)](/filings/0001522767-26-000073.md) | [1.0](/filings/0001522767-26-000167.md) | [1.6](/filings/0001522767-25-000224.md) | [(4.5) d](/filings/0001522767-26-000030.md) | [0.1](/filings/0001522767-26-000073.md) | [0.4](/filings/0001522767-26-000167.md) |
| Interest expense | $m | [2.5](/filings/0001522767-23-000123.md) | [1.6 d](/filings/0001522767-24-000007.md) | [1.6](/filings/0001522767-24-000042.md) | [1.7](/filings/0001522767-25-000169.md) | [1.7](/filings/0001522767-25-000224.md) | [1.9 d](/filings/0001522767-26-000030.md) | [1.8](/filings/0001522767-26-000073.md) | [1.8](/filings/0001522767-26-000167.md) | [1.8](/filings/0001522767-25-000224.md) | [2.2 d](/filings/0001522767-26-000030.md) | [2.0](/filings/0001522767-26-000073.md) | [2.0](/filings/0001522767-26-000167.md) |
| Income tax | $m | [4.5](/filings/0001522767-24-000091.md) | [0.5 d](/filings/0001522767-25-000014.md) | [1.7](/filings/0001522767-25-000052.md) | [0.9](/filings/0001522767-25-000169.md) | [0.7](/filings/0001522767-25-000224.md) | [4.9 d](/filings/0001522767-26-000030.md) | [2.8](/filings/0001522767-26-000073.md) | [0.7](/filings/0001522767-26-000167.md) | [2.8](/filings/0001522767-25-000224.md) | [(2.7) d](/filings/0001522767-26-000030.md) | [2.7](/filings/0001522767-26-000073.md) | [2.0](/filings/0001522767-26-000167.md) |
| Net income | $m | [(4.3)](/filings/0001522767-24-000091.md) | [(10.2) d](/filings/0001522767-25-000014.md) | [(1.3)](/filings/0001522767-25-000052.md) | [(1.7)](/filings/0001522767-25-000169.md) | [(1.0)](/filings/0001522767-25-000224.md) | [(8.3) d](/filings/0001522767-26-000030.md) | [(5.5)](/filings/0001522767-26-000073.md) | [(1.4)](/filings/0001522767-26-000167.md) | [(2.9)](/filings/0001522767-25-000224.md) | [(4.6) d](/filings/0001522767-26-000030.md) | [(3.8)](/filings/0001522767-26-000073.md) | [(3.6)](/filings/0001522767-26-000167.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001522767-24-000091.md) | not reported | [0.00](/filings/0001522767-25-000052.md) | [0.00](/filings/0001522767-25-000169.md) | [0.00](/filings/0001522767-25-000224.md) | not reported | [(0.01)](/filings/0001522767-26-000073.md) | [0.00](/filings/0001522767-26-000167.md) | [(0.01)](/filings/0001522767-25-000224.md) | not reported | [(0.01)](/filings/0001522767-26-000073.md) | [(0.01)](/filings/0001522767-26-000167.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001522767-24-000091.md) | not reported | [0.00](/filings/0001522767-25-000052.md) | [0.00](/filings/0001522767-25-000169.md) | [0.00](/filings/0001522767-25-000224.md) | not reported | [(0.01)](/filings/0001522767-26-000073.md) | [0.00](/filings/0001522767-26-000167.md) | [(0.01)](/filings/0001522767-25-000224.md) | not reported | [(0.01)](/filings/0001522767-26-000073.md) | [(0.01)](/filings/0001522767-26-000167.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [13.3](/filings/0001522767-23-000123.md) | [14.6](/filings/0001522767-25-000014.md) | [15.2](/filings/0001522767-24-000042.md) | [10.2](/filings/0001522767-24-000065.md) | [9.8](/filings/0001522767-24-000091.md) | [7.3](/filings/0001522767-25-000224.md) | [7.2](/filings/0001522767-25-000052.md) | [6.1](/filings/0001522767-25-000169.md) | [6.6](/filings/0001522767-25-000224.md) | not reported | not reported | not reported |
| Current assets | $m | [50.8](/filings/0001522767-23-000123.md) | [51.4](/filings/0001522767-25-000014.md) | [54.9](/filings/0001522767-24-000042.md) | [53.1](/filings/0001522767-24-000065.md) | [56.7](/filings/0001522767-24-000091.md) | [53.5](/filings/0001522767-26-000030.md) | [58.0](/filings/0001522767-25-000052.md) | [57.1](/filings/0001522767-25-000169.md) | [60.1](/filings/0001522767-25-000224.md) | [59.3](/filings/0001522767-26-000167.md) | [60.8](/filings/0001522767-26-000073.md) | [58.4](/filings/0001522767-26-000167.md) |
| Total assets | $m | [191](/filings/0001522767-23-000123.md) | [196](/filings/0001522767-25-000014.md) | [201](/filings/0001522767-24-000042.md) | [209](/filings/0001522767-24-000065.md) | [213](/filings/0001522767-24-000091.md) | [207](/filings/0001522767-26-000030.md) | [208](/filings/0001522767-25-000052.md) | [204](/filings/0001522767-25-000169.md) | [206](/filings/0001522767-25-000224.md) | [203](/filings/0001522767-26-000167.md) | [201](/filings/0001522767-26-000073.md) | [197](/filings/0001522767-26-000167.md) |
| Current liabilities | $m | [35.3](/filings/0001522767-23-000123.md) | [30.9](/filings/0001522767-25-000014.md) | [35.5](/filings/0001522767-24-000042.md) | [40.7](/filings/0001522767-24-000065.md) | [44.6](/filings/0001522767-24-000091.md) | [50.0](/filings/0001522767-26-000030.md) | [55.3](/filings/0001522767-25-000052.md) | [50.9](/filings/0001522767-25-000169.md) | [56.6](/filings/0001522767-25-000224.md) | [59.1](/filings/0001522767-26-000167.md) | [63.8](/filings/0001522767-26-000073.md) | [63.8](/filings/0001522767-26-000167.md) |
| Total liabilities | $m | [92.0](/filings/0001522767-23-000123.md) | [107](/filings/0001522767-25-000014.md) | [114](/filings/0001522767-24-000042.md) | [121](/filings/0001522767-24-000065.md) | [126](/filings/0001522767-24-000091.md) | [129](/filings/0001522767-26-000030.md) | [134](/filings/0001522767-25-000052.md) | [131](/filings/0001522767-25-000169.md) | [137](/filings/0001522767-25-000224.md) | [138](/filings/0001522767-26-000167.md) | [148](/filings/0001522767-26-000073.md) | [147](/filings/0001522767-26-000167.md) |
| Long-term debt | $m | [31.2](/filings/0001522767-23-000123.md) | not reported | [76.6](/filings/0001522767-24-000042.md) | [79.5](/filings/0001522767-24-000065.md) | [79.4](/filings/0001522767-24-000091.md) | [78.2](/filings/0001522767-25-000014.md) | [77.4](/filings/0001522767-25-000052.md) | [77.5](/filings/0001522767-25-000169.md) | [76.2](/filings/0001522767-25-000224.md) | [76.0](/filings/0001522767-26-000030.md) | [82.5](/filings/0001522767-26-000073.md) | [82.7](/filings/0001522767-26-000167.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [79.9](/filings/0001522767-24-000091.md) | [68.9](/filings/0001522767-26-000030.md) | [67.7](/filings/0001522767-25-000224.md) | [67.3](/filings/0001522767-25-000224.md) | [66.6](/filings/0001522767-25-000224.md) | [58.5](/filings/0001522767-26-000167.md) | [57.8](/filings/0001522767-26-000167.md) | [56.9](/filings/0001522767-26-000167.md) | [54.3](/filings/0001522767-25-000224.md) | [50.0](/filings/0001522767-26-000167.md) | [46.5](/filings/0001522767-26-000167.md) | [43.2](/filings/0001522767-26-000167.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [7,900 d](/filings/0001522767-24-000091.md) | [3,234 d](/filings/0001522767-25-000014.md) | [3,210](/filings/0001522767-25-000052.md) | [3,185 d](/filings/0001522767-25-000169.md) | [803 d](/filings/0001522767-25-000224.md) | [(413) d](/filings/0001522767-26-000030.md) | [1,293](/filings/0001522767-26-000073.md) | [297 d](/filings/0001522767-26-000167.md) | [2,676 d](/filings/0001522767-25-000224.md) | [3,429 d](/filings/0001522767-26-000030.md) | [949](/filings/0001522767-26-000073.md) | [2,219 d](/filings/0001522767-26-000167.md) |
| Capital expenditure | $k | [5,963 d](/filings/0001522767-24-000091.md) | [5,381 d](/filings/0001522767-25-000014.md) | [3,368](/filings/0001522767-25-000052.md) | [4,968 d](/filings/0001522767-25-000169.md) | [2,566 d](/filings/0001522767-25-000224.md) | [1,058 d](/filings/0001522767-26-000030.md) | [266](/filings/0001522767-26-000073.md) | [309 d](/filings/0001522767-26-000167.md) | [559 d](/filings/0001522767-25-000224.md) | [33.0 d](/filings/0001522767-26-000030.md) | [373](/filings/0001522767-26-000073.md) | [298 d](/filings/0001522767-26-000167.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [381](/filings/0001522767-23-000123.md) | [343](/filings/0001522767-24-000042.md) | [361](/filings/0001522767-24-000065.md) | [373](/filings/0001522767-24-000091.md) | [375](/filings/0001522767-25-000052.md) | [380](/filings/0001522767-25-000169.md) | [381](/filings/0001522767-25-000224.md) | [383](/filings/0001522767-26-000073.md) | [390](/filings/0001522767-26-000167.md) | [393](/filings/0001522767-25-000224.md) | [397](/filings/0001522767-26-000073.md) | [400](/filings/0001522767-26-000167.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 403,040,674 at 2026-08-10, from the cover of the [10-Q filed 2026-08-13](/filings/0001522767-26-000167.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.